.jpg)
.jpg)
Shares of the innovative clinical-stage biotechnology company bluebird bio Inc. (NASDAQ: BLUE) have jumped more than 13% Tuesday, after the company together with their partner Celgene Corporation (NASDAQ: CELG) reported updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma. Shares are up more than 67% year to date.
The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. bluebird bio and Celgene are jointly developing bb2121.
Highlights:
- 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 106) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89%
- 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete response (CR) rate across active dose cohorts
- All patients tested for minimal residual disease (MRD) status (n=4) were found to be MRD-negative
- No disease progression has been observed in active dose cohorts as of May 4, 2017 data cut-off; range of follow-up was 8 to 54 weeks
- No dose-limiting toxicities have been observed
“It is impressive to see objective responses in all patients treated at dose levels of 150 x 106 CAR+ T cells or higher in such a heavily pretreated population, including those with high tumor burden. We are encouraged by the duration and depth of responses, and pleased that the safety profile remains readily manageable,” said David Davidson, M.D., chief medical officer, bluebird bio. “Although these data are still early, it is encouraging that no patient in the active dose cohorts has had myeloma progression. In light of these results, we look forward to initiating the expansion phase of the CRB-401 study in the coming months.”
“The heavily pretreated, relapsed/refractory patients in this study have few effective treatment options, highlighting the importance of this interim data. All patients previously underwent autologous HSCT, and received a median of 7 lines of prior therapy,” said Michael Pehl, President, Hematology and Oncology for Celgene. “The consistency, depth and durability of these patients’ responses coupled with a manageable safety profile is very exciting, and we believe will provide hope for patients in this setting. Efforts are underway to advance the development of bb2121 for patients with relapsed/refractory multiple myeloma.”
bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene.
.jpg){kind=small}
9 Comments
kd shoes
Jun 24, 2023 at 06 44 pmThere are actually lots of particulars like that to take into consideration. That could be a great level to bring up. I provide the ideas above as general inspiration however clearly there are questions just like the one you bring up where an important factor can be working in sincere good faith. I don?t know if best practices have emerged round things like that, but I am positive that your job is clearly identified as a good game. Each boys and girls really feel the impression of only a second抯 pleasure, for the rest of their lives.
kd shoes http://www.kd14shoes.com
yeezy shoes
Jun 27, 2023 at 07 41 amGood post. I study something more challenging on completely different blogs everyday. It'll always be stimulating to read content material from different writers and follow a bit of one thing from their store. I抎 choose to use some with the content on my weblog whether or not you don抰 mind. Natually I抣l offer you a link on your web blog. Thanks for sharing.
yeezy shoes http://www.yeezy-shoes.us.org
hermes
Jun 30, 2023 at 10 25 amSpot on with this write-up, I truly assume this web site wants far more consideration. I抣l in all probability be again to learn rather more, thanks for that info.
hermes http://www.hermesoutlets.com
palm angels
Jul 01, 2023 at 12 54 amThere are certainly a lot of particulars like that to take into consideration. That may be a great point to convey up. I provide the ideas above as general inspiration however clearly there are questions like the one you carry up the place the most important factor will be working in sincere good faith. I don?t know if finest practices have emerged around things like that, but I am positive that your job is clearly recognized as a good game. Each boys and girls feel the affect of just a moment抯 pleasure, for the rest of their lives.
palm angels http://www.palmangels-outlet.com
bathing ape
Jul 01, 2023 at 04 53 pmIt抯 laborious to find knowledgeable individuals on this topic, however you sound like you already know what you抮e talking about! Thanks
bathing ape http://www.bapes.us.org
kyrie irving shoes
Jul 08, 2023 at 01 45 amCan I just say what a reduction to seek out someone who truly is aware of what theyre speaking about on the internet. You undoubtedly know easy methods to bring an issue to gentle and make it important. Extra individuals have to learn this and perceive this facet of the story. I cant believe youre no more fashionable since you definitely have the gift.
kyrie irving shoes http://www.kyrieirving-shoes.us.com
supreme outlet
Jul 13, 2023 at 02 31 amOh my goodness! an incredible article dude. Thanks Nonetheless I am experiencing issue with ur rss . Don抰 know why Unable to subscribe to it. Is there anyone getting identical rss problem? Anyone who is aware of kindly respond. Thnkx
supreme outlet http://www.supremenewyork.us.org
bape
Jul 13, 2023 at 08 55 pmAw, this was a really nice post. In concept I want to put in writing like this additionally ?taking time and precise effort to make an excellent article?but what can I say?I procrastinate alot and not at all seem to get one thing done.
bape http://www.bathing-ape.us
yeezy shoes
Jul 16, 2023 at 04 17 amHowdy! I simply would like to give an enormous thumbs up for the good information you will have right here on this post. I will be coming again to your blog for extra soon.
yeezy shoes http://www.yeezy-shoes.us.org